It’s a brave new world for SomaLogic, as the proteomics biotech rides Eli Casdin’s newest SPAC to Nasdaq with $1.2B valuation

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

The burgeoning field of proteomics has courted heavy investment over the last few years, and on Monday a prominent proteomics biotech scored a new heaping of capital.

SomaLogic announced plans to...

Click to view original post